Welcome to our dedicated page for Bioxytran news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.
Bioxytran, Inc. develops carbohydrate-based biotechnology programs focused on hypoxia, viral diseases, inflammation, metabolic health, and degenerative disease. News about BIXT commonly centers on ProLectin-M, its investigational oral antiviral candidate, including clinical study results, dose-optimization work, viral-clearance data, and regulatory-discussion updates for later-stage development.
Company updates also cover Bioxytran’s galectin-targeting platform, research collaborations involving polysaccharide and oligosaccharide interactions, and applications such as PHM23 in avian influenza research. Commercial news includes A-SUQAR®, a chewable dietary supplement containing a proprietary partially hydrolyzed guar gum formulation, along with distribution agreements and private-placement financing used for working capital and development programs.
Bioxytran (OTC: BIXT) completed a private placement on March 18, 2026, raising approximately $1.2 million. The company issued about 21,071,667 common shares at ~$0.055 per share and warrants to buy up to 19,750,001 shares at $0.12, five-year term.
The company said it will use net proceeds for working capital, development programs, and selected commercialization, including an A-SUQAR® dietary supplement launch expected this quarter.
Bioxytran (OTCQB: BIXT) reported positive dose optimization for ProLectin-M and outlined plans toward a Phase 3 registrational trial. A 39-participant study identified a 16,800 mg/day regimen achieving 90% viral clearance by Day 5 with a favorable safety profile. The company is in discussions with the FDA and India’s CDSCO and proposes a ~408‑participant randomized, placebo-controlled outpatient Phase 3 trial for standard‑risk patients with mild‑to‑moderate COVID-19 and other viral infections.
Bioxytran also reported in vitro activity versus RSV and H1N1, a University of Georgia collaboration on H5N1 research, and advancement of an IV formulation for Long COVID.
Bioxytran (OTCQB:BIXT) reported Phase 1b/2a results for oral ProLectin-M in mild‑to‑moderate COVID‑19 on March 2, 2026. The highest dose (16,800 mg/day) produced statistically significant earlier viral clearance and faster clinical improvement by Day 5 versus placebo (p=0.001), with no serious adverse events reported.
Study enrolled 39 participants across four arms; by Day 7 viral clearance occurred across all arms, consistent with expected natural recovery. Company plans further larger studies to evaluate ProLectin-M's galectin‑targeting mechanism and oral therapeutic potential.
Bioxytran (OTCQB:BIXT) initiated a research collaboration with the University of Georgia on February 23, 2026 to evaluate its lead candidate PHM23 against Highly Pathogenic Avian Influenza H5N1.
The program follows an NDA from March 2025 and was included in UGA's submission to the USDA's $100M HPAI Poultry Innovation Grand Challenge. In vitro data versus viruses similar to H5N1 support further study.
Bioxytran (OTCQB:BIXT) announced a commercial Distribution Agreement with Khoury Medical LTD to commercialize A-SUQAR, a chewable dietary supplement containing Bioxytran's proprietary partially hydrolyzed guar gum (PHGG), in permitted markets.
The agreement preserves Bioxytran's pharmaceutical rights, uses OEM manufacturing, and offers potential volume-based marketplace exclusivity subject to purchase thresholds and conditions.
Bioxytran (OTCQB: BIXT) reported positive Phase 2 results for orally administered ProLectin-M in 38 subjects with acute viral infection. The trial showed 100% viral RNA non-detection by Day 7 (p=0.001), no viral rebounds during a 14-day post-treatment observation, and informed a four-tablet-per-day dose selection for late-stage development.
Bioxytran (OTCQB:BIXT) announced that CEO David Platt, Ph.D. will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 5, 2026. The presentation includes a fireside Q&A and will overview corporate strategy, pipeline focus, and previously disclosed clinical and regulatory progress.
A video webcast will be available after the event and archived on the company website and Channelchek.com for 90 days.
Bioxytran (OTCQB: BIXT) executed a Sponsored Research Agreement with the University of Minnesota to study polysaccharide and oligosaccharide interactions using advanced nuclear magnetic resonance (NMR) methods under Dr. Kevin Mayo. The program runs through early 2027 with milestones, funding for personnel and NMR access, and university IP ownership with broad data rights for Bioxytran.
The collaboration aims to deepen structural understanding of carbohydrate-binding interactions to inform Bioxytran's therapeutic and diagnostic R&D pathways.
Bioxytran (OTCQB:BIXT) issued a corporate update on January 29, 2026 highlighting progress across its ProLectin‑M antiviral program, an active U.S. FDA IND, dose-optimization completion, and work on an oxygen-transport platform including a joint venture with the Heme Foundation.
The release reiterates prior milestones: completion of a randomized, double-blind, placebo-controlled ProLectin‑M trial in October 2025, dose-optimization work in May 2025, a July 2024 JV for a universal oxygen carrier, and a January 2025 cancer-focused galectin‑3 preprint.
Bioxytran (OTCQB:BIXT) announced on Nov 13, 2025 that Independent Research initiated coverage of the stock and published a report highlighting clinical and corporate updates.
Key clinical data for lead candidate ProLectin-M: 88% viral clearance by day 3 and 100% by day 7 in mild-to-moderate COVID-19, with no serious adverse events reported. The drug targets the galectin fold and is positioned as a potential broad-spectrum antiviral.
Pipeline focus includes ambulatory stroke candidate BXT-25 aimed at expanding the 3-hour treatment window. The report flags funding as the primary risk and notes >50% insider ownership and active pursuit of strategic partnerships.